Product Description
The Competitive Intelligence Report Emerging Diabetes Drugs & Targets as of November 2008 provides a competitor analysis in the development pipeline of novel emerging antidiabetic treatment modalities for type 1 and 2 diabetes beyond the established targets PPAR agonists, DPP-IV inhibitors, GLP-1 receptor agonists and SGLT inhibitors. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for establis… More >>
Competitor Analysis: Emerging Diabetes Drugs
